KIMBERLY HARBIN: Open Payments
NPI 1790731867 · CAIRO, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$846 in 27 payments from 10 companies in 2025. Trend: 2023 $665 · 2024 $818 · 2025 $846
Food & beverage: $846
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 9 | $214 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $201 |
| Novo Nordisk Inc | 3 | $144 |
| Corcept Therapeutics | 2 | $122 |
| AstraZeneca Pharmaceuticals LP | 2 | $45 |
| GlaxoSmithKline, LLC. | 2 | $44 |
| Astellas Pharma US Inc | 1 | $22 |
| ABBVIE INC. | 1 | $20 |
| Exact Sciences Corporation | 1 | $17 |
| Novartis Pharmaceuticals Corporation | 1 | $16 |
Products named: Kerendia, REPATHA, Ozempic, Korlym, OTEZLA, AIRSUPRA, TRELEGY ELLIPTA, Veozah.
Industry payments across GA — which companies pay providers there.
